Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
June, 2026
June 2026
M T W T F S S
1234567
891011121314
15161718192021
22232425262728
2930  
Zafer Tandogdu: Can TXA Redefine Bleeding Management in Urology
Daniel Jiménez Peralta/LinkedIn;Zafer Tandogdu/LinkedIn
May 17, 2026, 12:41

Zafer Tandogdu: Can TXA Redefine Bleeding Management in Urology

Zafer Tandogdu, Consultant Urologist, Member of Uro-oncology Robotic Surgery Team at University College London Hospitals NHS Foundation Trust, Senior Researcher and co-founder of UTISOLVE Research Group, shared Daniel Jiménez Peralta’s post on LinkedIn:

“Shout it from the rooftops: tranexamic acid reduces surgical bleeding, transfusion need, and major bleeding — without an observed increase in thromboembolic events.

Use it thoughtfully, but don’t fear it reflexively.”

Daniel Jiménez Peralta, Digital Health Office Collaborator at Spanish Association of Urology, Urologist at the La Rioja Health Service, shared a post on LinkedIn:

“Everything we assumed about tranexamic acid in urology had never really been proven.

Until now.

Kari Tikkinen — thank you for bringing this question to the table.

For years, young urologists like me saw tranexamic acid being used by other specialties during high risk of bleeding while we looked the other way.

The EAU and AUA guidelines did not clearly recommend it.

The prior evidence was inconsistent.

And the fear of thrombotic events outweighed the perceived benefit.

Until the urology subgroup analysis of POISE-3 arrived.

  • 1,124 patients.
  • High cardiovascular-risk urologic surgery.
  • 1 g of TXA at induction plus 1 g at closure.

The results:

  • Major bleeding: 6.1 percent versus 9.5 percent (HR 0.63)
  • 37 percent relative risk reduction
  • No clear signal of increased thrombotic events

What does this mean in practice?

For every 1,000 patients operated on, 34 major bleeds avoided.

In cystectomies. In open nephrectomies. In older patients with cardiovascular risk and on antithrombotic therapy.

TXA is inexpensive. It’s accessible. And now it has robust evidence.

Are you already using it in your department?

What has your experience been?”

Zafer Tandogdu: Can TXA Redefine Bleeding Management in Urology

Stay updated with Hemostasis Today.

AUA bleeding Daniel Jiménez Peralta EAU Health Hematology Hemostasis News Hemostasis Today Medicine TXA Urology Zafer Tandogdu
NewsFeed